A structured research digest on ipamorelin's safety record, combination stacks, and the evidence behind them.
Safe Ipamorelin

The literature

Ipamorelin research: mechanism, the studies that defined it, and the combination-stack rationale

Single-agent findings and combination pharmacology, each kept in its own column and cited to source.

Start here

The ipamorelin research record is unusually lopsided, and it helps to know that before reading it. The animal pharmacology is deep and clean: ipamorelin releases growth hormone potently and selectively, and it does so by a mechanism that pairs naturally with a different class of GH-releasing drug. The human record is shallow and mostly negative: one small pharmacology study and one failed Phase 2 trial. This page walks through the mechanism (how it works), the founding study that defined its selectivity, what little human data exists, the bone-growth and recent animal findings, and the published reason ipamorelin is paired with GHRH analogs like CJC-1295. A few studies cited here use related peptides (GHRP-6, GHRP-2) to establish a class-level principle — those are flagged in the text so combination claims are never overstated as ipamorelin-specific.

Mechanism — a selective ghrelin-receptor agonist

Ipamorelin activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the GH-producing cells — triggering a pulse of GH release through the Gq/phospholipase-C/calcium pathway. Its signature is what it does not do: it leaves ACTH, cortisol, and prolactin essentially untouched even far above its GH threshold [1]. Because it releases GH by a route distinct from growth-hormone-releasing hormone (GHRH), its action is complementary to GHRH rather than redundant — the molecular basis for combination stacks [7]. Downstream, GH can raise hepatic IGF-1, though short rodent studies often show no IGF-1 change, indicating part of the early effect is a direct GH-pulse phenomenon [4]. Peripheral GHS-R signaling also reaches pancreatic islets and enteric neurons, which is why metabolic and gut-motility effects appear in the literature.

The founding study — defining selectivity

Ipamorelin entered the literature in 1998 as "the first selective growth hormone secretagogue" [1]. In primary rat pituitary cells, anaesthetized rats, and conscious swine, it released GH potently — the swine dose for half-maximal effect was 2.3 nmol/kg, against 3.9 nmol/kg for GHRP-6 — yet it did not raise ACTH or cortisol above the GHRH baseline even at doses more than 200-fold above the GH threshold [1]. That single result is why ipamorelin outlived most of its GHRP contemporaries: it decoupled GH release from the stress-axis activation that limited the others. The characterization was acute, not chronic — it says nothing about what repeated dosing does over months.

Human data — limited and mostly negative

Two human datasets exist, and they bracket the whole human record. The first, a population PK/PD study in healthy male volunteers (n=8 per dose, five IV infusions of 4.21–140.45 nmol/kg), found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a single GH pulse peaking near 40 minutes after dosing [2]. The second, the only published Phase 2 RCT (NCT00672074), gave 0.03 mg/kg IV twice daily for up to 7 days to 114 bowel-resection patients and missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short window, but no efficacy either [3].

Bone growth and the most recent in-vivo finding

In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 micrometers/day on vehicle to 44, 50, and 52 — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The decoupling of a skeletal effect from systemic IGF-1 points to a local, GH-pulse-driven mechanism. The freshest in-vivo data is a 2024 ferret study: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by roughly 24% during the delayed phase, but had no anti-emetic effect — in contrast to central anamorelin, which cut acute emesis by 60% [5]. The weight-protection effect was peripheral.

The combination rationale — why GHRH + GHRP

The pharmacological case for stacking is class-level and well documented. A comprehensive review established that all GHRPs act synergistically with GHRH and are partially resistant to the inhibitory signals — glucose, free fatty acids, somatostatin — that nearly abolish GHRH on its own [7]. A neuroendocrine review adds the circuit detail: ghrelin (and synthetic GHS-R1a agonists by extension) co-localizes with GHRH neurons, facilitates GHRH release by inhibiting somatostatin, and synergizes with GHRH at the pituitary — dual amplification [9]. In lambs, low-dose GHRP-6 plus GHRH produced higher GH peak and area-under-curve than GHRH alone (p<0.05) [10]. The long-acting GHRH partner most discussed with ipamorelin, CJC-1295, produced dose-dependent 2- to 10-fold GH increases for six-plus days and 1.5- to 3-fold sustained IGF-1 elevation after a single subcutaneous dose in healthy adults, while preserving pulsatile secretion [11]. Note carefully: studies [7], [9], and [10] use related peptides or review data to establish a class principle, and [11] is on CJC-1295, not ipamorelin. The combination of ipamorelin and CJC-1295 has not itself been tested for any outcome.

Is ipamorelin FDA approved

Is ipamorelin FDA approved? No. Ipamorelin has never been approved by the FDA — or by any other regulatory authority — as a drug for any indication. It was investigated for postoperative ileus (NCT00672074) but never approved, and that trial failed its primary endpoint [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following nominator withdrawal, and reviewed both the acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2 [12].

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is a comparison of two different mechanisms, not two versions of one drug. Ipamorelin is a GHRP — it acts on the ghrelin receptor (GHS-R1a) to release GH [1]. Tesamorelin is a GHRH analog — it acts on the GHRH receptor. The most consequential difference is regulatory: tesamorelin is an approved drug (for a specific HIV-associated condition), whereas ipamorelin has no approved indication anywhere and failed its only Phase 2 trial [3]. Mechanistically the two are complementary classes, which is why a GHRP is typically paired with a GHRH analog rather than swapped for one; the class-level synergy between GHRP and GHRH is documented across the review literature [7].